



and a pharmaceutically acceptable carrier.

5. (Twice amended) A method of antagonizing A<sub>2B</sub> receptors comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:




wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

6. (Twice amended) A method of treating asthma comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:




wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

7. (Twice amended) A method of treating diarrhea comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:




wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

8. (Twice amended) A method of regulating at least one of smooth muscle tone, blood vessel growth, and A<sub>2B</sub> antagonist mediated neurotransmitter secretion comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:




wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

9. (Twice amended) A method of treating inflammatory gastrointestinal tract disorders comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:



wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.


10. (Twice amended) A method of treating depression comprising administering to a mammal in need thereof an effective amount of a compound of the following formula:



wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.


12. (Twice amended) A method treating a disease selected from the group consisting of: arthritis, asthma, multiple sclerosis, septic shock, endotoxic shock, gram negative shock, toxic shock, hemorrhagic shock, adult respiratory distress syndrome, organ transplant rejection, cachexia secondary to cancer, osteoporosis, infertility from endometriosis, bacterial meningitis, adverse effects from amphotericin B treatment, adverse effects from interleukin-2 treatment, adverse effects from OKT3 treatment, or

adverse effects from GM-CSF treatment comprising administering to a mammal in need thereof, an effective amount of a compound of the following formula:




wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

19. (Twice amended) A method of modulating human mast cell function comprising administering to a patient in need thereof an effective amount of a compound of the following formula:



wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.


22. (Once amended) A compound of the following formula:



wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.


Please add the following new claims 24-26 to the application:

24. (New) A compound of the following formula:




or a pharmaceutically acceptable salt thereof, wherein R is cycloaliphatic amine.

25. (New) A method of treating inflammatory diseases, comprising administering to a mammal in need thereof an effective amount of a compound of the formula:



wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

26. (New) A method of treating cardiac disease comprising administering to a patient in need thereof an effective amount of a compound of the formula:



wherein R is selected from C<sub>1</sub> to C<sub>6</sub> alkyl amine, C<sub>1</sub> to C<sub>6</sub> dialkyl amine, ~~unsubstituted~~ piperidino, piperazino, pyrrolidino, pyrrolino, morpholino, an amino cyclohexyl derivative or a pharmaceutically acceptable salt thereof.

### REMARKS

Claims 4-10, 12-19, 22 and 23 were pending as of the May 15, 2002 Official Action. While not necessarily in agreement with the rejections made by the Examiner, Applicants have amended the claims to expedite review and allowance. Applicants also reserve the right to prosecute any canceled claim matter in later applications. Claim 8 has been amended in response to the Examiner's suggestions. Claims 4, 5, 6, 7, 8, 9, 10, 12, 19, and 22 have been amended to bring them into accord with the below arguments on obviousness. Claims 24, 25, and 26 have been added to claim scope Applicants believe they are entitled to in view of the Examiner's cited documents.

#### **I. General Comments on the Examiner's Final Rejection**

The Final Action, the Examiner rejected claims 4-6, 12-19 and 22. The Examiner allowed claims 7-10 and 23. There is a minor inconsistency with the identification of the rejected and allowed claims in the Final Rejection. Claim 8 was rejected under Section